Hematologic Malignancy
Follicular Lymphoma
CI-CAN-00005316Explore in graph →
Hematologic216 active trials8 approved drugs12 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005316Explore in graph →
Clinical trials
775 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (149)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06313996 | A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma | withdrawn | Phase 3 | 0 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 0 | Mar 18, 2026 | clinicaltrials |
| NCT04796922 | To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) | withdrawn | Phase 3 | 0 | Incyte CorporationINDUSTRY | 0 |
| Jul 18, 2022 |
| clinicaltrials |
| NCT00319332 | A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen | withdrawn | Phase 3 | 0 | GlaxoSmithKlineINDUSTRY | 1 | Apr 17, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Mar 18, 2026source: clinicaltrials